Clinical Research
Filter News
Found 128,866 articles
-
Ophthalmology has become a focal point for private equity and venture capitalists in the past 18 months, despite being a small niche in the biopharmaceutical space.
-
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
8/3/2021
AXIM Biotechnologies, Inc announced today that the Company has signed a Binding Term Sheet to acquire the technology for the testing of Dry Eye Disease (DED), including two FDA authorizations and approvals for the commercial sale of two ophthalmic diagnostic lab tests.
-
LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
8/3/2021
Lixte Biotechnology Holdings, Inc. announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer.
-
Veranex Announces Acquisition of Experien Group
8/3/2021
Veranex today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
-
U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration
8/3/2021
Allegro Ophthalmics today announced that the results of the company’s U.S. Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.
-
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
8/3/2021
Abbott today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software.
-
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
8/3/2021
Catalent, Inc. announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.
-
Pulnovo Medical recently raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong Capital
8/3/2021
Pulnovo Medical recently raised millions of dollars through OrbiMed, Cenova, Lilly Asia Ventures (LAV), and GaoRong Capital.
-
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology
8/3/2021
Iterative Scopes today disclosed that it has closed a $30 million Series A financing.
-
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
8/3/2021
Zymeworks Inc. today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
-
Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent
8/3/2021
Viveve Medical, Inc. today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve's dual-energy technology device and method.
-
Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
8/3/2021
Ambrx today announced the first patient has been dosed in a Phase 1, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of ARX517 in subjects with prostate specific membrane antigen (PSMA).
-
Engrail Therapeutics Extends Series A Financing to $64 Million
8/3/2021
Engrail Therapeutics™ today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.
-
Resolve Biosciences and ZEISS Announce Co-Development Collaboration to Enhance Highest-Resolution View of Subcellular Spatial Biology
8/3/2021
Resolve Biosciences, the pioneer in Molecular Cartography™, and ZEISS today announced a co-development collaboration to advance spatial biology applications.
-
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
8/3/2021
Hancock Jaffe Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the VenoValve®
-
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
8/3/2021
Arcturus Therapeutics Holdings Inc. announced that the Company has received approval for a Clinical Trial Application from the Singapore Health Sciences Authority to enable the advancement of two STARR™ mRNA vaccine candidates into the clinic.
-
OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
8/3/2021
OpGen, Inc. today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform.
-
BGN Technologies Introduces New Method for Identifying Bacteria and Their Susceptibility to Antibiotics
8/3/2021
Novel technology, based on infrared spectroscopy, can accurately determine identity of pathogens and their susceptibility to antibiotics resistance in 30-40 minutes, directly from urine sample of patients
-
Veeva Acquires Learnaboutgmp, a Leading GxP eLearning Content Provider
8/3/2021
Companies join forces to improve training efficiency and compliance with industry-leading content and technology
-
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
8/3/2021
Orion obtains rights to commercialize both the oral and IV franchises of ganaxolone in Europe. Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion’s expertise in rare orphan diseases, antiepileptics and European commercialization